Effects of Consumption of Pomegranate Juice on Carotid Intima–Media Thickness in Men and Women at Moderate Risk for Coronary Heart Disease

      This randomized, double-blind, parallel trial assessed the influence of pomegranate juice consumption on anterior and posterior carotid intima–media thickness (CIMT) progression rates in subjects at moderate risk for coronary heart disease. Subjects were men (45 to 74 years old) and women (55 to 74 years old) with ≥1 major coronary heart disease risk factor and baseline posterior wall CIMT 0.7 to 2.0 mm, without significant stenosis. Participants consumed 240 ml/day of pomegranate juice (n = 146) or a control beverage (n = 143) for up to 18 months. No significant difference in overall CIMT progression rate was observed between pomegranate juice and control treatments. In exploratory analyses, in subjects in the most adverse tertiles for baseline serum lipid peroxides, triglycerides (TGs), high-density lipoprotein (HDL) cholesterol, TGs/HDL cholesterol, total cholesterol/HDL cholesterol, and apolipoprotein-B100, those in the pomegranate juice group had significantly less anterior wall and/or composite CIMT progression versus control subjects. In conclusion, these results suggest that in subjects at moderate coronary heart disease risk, pomegranate juice consumption had no significant effect on overall CIMT progression rate but may have slowed CIMT progression in subjects with increased oxidative stress and disturbances in the TG-rich lipoprotein/HDL axis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gil M.I.
        • Tomás-Barberán F.A.
        • Hess-Pierce B.
        • Holcroft D.M.
        • Kader A.A.
        Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing.
        J Agric Food Chem. 2000; 48: 4581-4589
        • Aviram M.
        • Dornfeld L.
        • Rosenblat M.
        • Volkova N.
        • Kaplan M.
        • Coleman R.
        • Hayek T.
        • Presser D.
        • Fuhrman B.
        Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice.
        Am J Clin Nutr. 2000; 71: 1062-1076
        • Aviram M.
        • Dornfeld L.
        Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure.
        Atherosclerosis. 2001; 158: 195-198
        • Kaplan M.
        • Hayek T.
        • Raz A.
        • Coleman R.
        • Dornfeld L.
        • Vaya J.
        • Aviram M.
        Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis.
        J Nutr. 2001; 131: 2082-2089
        • Aviram M.
        • Rosenblat M.
        • Gaitini D.
        • Nitecki S.
        • Hoffman A.
        • Dornfeld L.
        • Volkova N.
        • Presser D.
        • Attias J.
        • Liker H.
        • Hayek T.
        Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation.
        Clin Nutr. 2004; 23: 423-433
        • Sumner M.D.
        • Elliott-Eller M.
        • Weidner G.
        • Daubenmier J.J.
        • Chew M.H.
        • Marlin R.
        • Raisin C.J.
        • Ornish D.
        Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease.
        Am J Cardiol. 2005; 96: 810-814
        • Ignarro L.J.
        • Byrns R.E.
        • Sumi D.
        • de Nigris F.
        • Napoli C.
        Pomegranate juice protects nitric oxide against oxidative destruction and enhances the biological actions of nitric oxide.
        Nitric Oxide. 2006; 15: 93-102
        • Rosenblat M.
        • Hayek T.
        • Aviram M.
        Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages.
        Atherosclerosis. 2006; 187: 363-371
        • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
        Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
        • Mazzone T.
        • Meyer P.M.
        • Feinstein S.B.
        • Davidson M.H.
        • Kondos G.T.
        • D'Agostino Sr, R.B.
        • Perez A.
        • Provost J.C.
        • Haffner S.M.
        Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
        JAMA. 2006; 296: 2572-2581
        • Gariepy J.
        • Salomon J.
        • Denarié N.
        • Laskri F.
        • Megnien J.L.
        • Levenson J.
        • Simon A.
        Sex and topographic differences in associations between large-artery wall thickness and coronary risk profile in a French working cohort: the AXA study.
        Arterioscler Thromb Vasc Biol. 1998; 18: 584-590
        • Simon A.
        • Gariepy J.
        • Moyse D.
        • Levenson J.
        Differential effects of nifedipine and co-amilozide on progression of early carotid wall changes.
        Circulation. 2001; 103: 2949-2954
        • Macioch J.E.
        • Katsamakis C.D.
        • Robin J.
        • Liebson P.R.
        • Meyer P.M.
        • Geohas C.
        • Raichlen J.S.
        • Davidson M.H.
        • Feinstein S.B.
        Effect of contrast enhancement on measurement of carotid artery intimal medial thickness.
        Vasc Med. 2004; 9: 7-12
        • Ledue T.B.
        • Rifai N.
        High sensitivity immunoassays for C-reactive protein: promises and pitfalls.
        Clin Chem Lab Med. 2001; 39: 1171-1176
        • Benzie I.F.
        • Strain J.J.
        The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay.
        Anal Biochem. 1996; 239: 70-76
        • Gan K.
        • Smole A.
        • Eckerson H.W.
        • La Du B.N.
        Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities.
        Drug Metab Dispos. 1991; 19: 100-106
        • Frei B.
        • Stocker R.
        • Ames B.N.
        Antioxidant defenses and lipid peroxidation in human blood plasma.
        Proc Natl Acad Sci U S A. 1988; 85: 9748-9752
        • El-Saadani M.
        • Esterbauer N.
        • El-Sayed M.
        • Goher M.
        • Nassar A.Y.
        • Jurgens G.
        Spectrophotometric assay for lipid peroxides in serum lipoproteins using commercially available reagent.
        J Lipid Res. 1989; 30: 627-630
        • Buege J.A.
        • Aust S.D.
        Microsomal lipid peroxidation.
        Methods Enzymol. 1978; 52: 302-310
        • Bland J.M.
        • Altman D.G.
        Measuring agreement in method comparison studies.
        Stat Methods Med Res. 1999; 8: 135-160
        • Liu M.L.
        • Ylitalo K.
        • Salonen R.
        • Salonen J.T.
        • Taskinen M.R.
        Circulating oxidized low-density lipoprotein and its association with carotid intima-media thickness in asymptomatic members of familial combined hyperlipidemia.
        Arterioscler Thromb Vasc Biol. 2004; 24: 1492-1497
        • Wallenfeldt K.
        • Fagerberg B.
        • Wikstrand J.
        • Hulthe J.
        Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men.
        J Intern Med. 2004; 256: 413-420
      1. Carotid atorvastatin study in hyperlipidemic post-menopausal women: a randomized evaluation of atorvastatin versus placebo (CASHMERE).
        (Accessed November 16, 2008)
        • Brown B.G.
        • Taylor A.J.
        Does ENHANCE diminish confidence in lowering LDL or in ezetimibe.
        N Engl J Med. 2008; 358: 1504-1507
        • Drazen J.M.
        • Jarcho J.A.
        • Morrissey S.
        • Curfman G.D.
        Cholesterol lowering and ezetimibe.
        N Engl J Med. 2008; 358: 1507-1508
        • Kastelein J.J.P.
        • Akdim F.
        • Stroes E.S.
        • Zwinderman A.H.
        • Bots M.L.
        • Stalenhoef A.F.
        • Visseren F.L.
        • Sljbrands E.J.
        • Trip M.D.
        • Stein E.A.
        • Gaudet D.
        • Duivenvoorden R.
        • Veltri E.P.
        • Marais A.D.
        • de Groot E.
        • ENHANCE Investigators
        Simvastatin with or without ezetimibe in familial hypercholesterolemia.
        N Engl J Med. 2008; 358: 1431-1443
        • Stein E.A.
        Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: More clarity or confusion?.
        J Am Coll Cardiol. 2008; 52: 2206-2209
        • Poredos P.
        Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis.
        Vasc Med. 2004; 9: 46-54
        • Aviram M.
        Dietary antioxidants stimulate the expression of paraoxonases which provides protection against atherosclerosis development.
        Curr Top Nutraceutical Res. 2003; 3: 161-169
        • Polagruto J.A.
        • Schramm D.D.
        • Wang-Polagruto J.F.
        • Lee L.
        • Keen C.L.
        Effects of flavonoids-rich beverages on prostacyclin synthesis in humans and human aortic endothelial cells: association with ex vivo platelet function.
        J Med Food. 2003; 6: 301-308